Mesoblast Ltd (MSB) - Total Assets
Based on the latest financial reports, Mesoblast Ltd (MSB) holds total assets worth AU$784.68 Million AUD (≈ $555.21 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See MSB book value for net asset value and shareholders' equity analysis.
Mesoblast Ltd - Total Assets Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's total assets have evolved over time, based on quarterly financial data.
Mesoblast Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Mesoblast Ltd's total assets of AU$784.68 Million consist of 26.0% current assets and 74.0% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 20.5% |
| Accounts Receivable | AU$14.87 Million | 1.9% |
| Inventory | AU$22.25 Million | 2.8% |
| Property, Plant & Equipment | AU$5.82 Million | 0.7% |
| Intangible Assets | AU$437.37 Million | 55.7% |
| Goodwill | AU$134.45 Million | 17.1% |
Asset Composition Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Mesoblast Ltd stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Mesoblast Ltd's current assets represent 26.0% of total assets in 2025, a decrease from 71.4% in 2005.
- Cash Position: Cash and equivalents constituted 20.5% of total assets in 2025, down from 70.3% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 72.0% of total assets, an increase from 3.0% in 2005.
- Asset Diversification: The largest asset category is intangible assets at 55.7% of total assets.
Mesoblast Ltd Competitors by Total Assets
Key competitors of Mesoblast Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Mesoblast Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.99 | 1.18 | 1.32 |
| Quick Ratio | 1.77 | 1.15 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$101.72 Million | AU$13.22 Million | AU$28.04 Million |
Mesoblast Ltd - Advanced Valuation Insights
This section examines the relationship between Mesoblast Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.80 |
| Latest Market Cap to Assets Ratio | 2.55 |
| Asset Growth Rate (YoY) | 17.3% |
| Total Assets | AU$784.68 Million |
| Market Capitalization | $2.00 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Mesoblast Ltd's assets at a significant premium (2.55x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Mesoblast Ltd's assets grew by 17.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Mesoblast Ltd (2005–2025)
The table below shows the annual total assets of Mesoblast Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$784.68 Million ≈ $555.21 Million |
+17.27% |
| 2024-06-30 | AU$669.15 Million ≈ $473.47 Million |
-0.04% |
| 2023-06-30 | AU$669.41 Million ≈ $473.65 Million |
+1.10% |
| 2022-06-30 | AU$662.14 Million ≈ $468.51 Million |
-11.09% |
| 2021-06-30 | AU$744.72 Million ≈ $526.93 Million |
+1.52% |
| 2020-06-30 | AU$733.60 Million ≈ $519.07 Million |
+12.50% |
| 2019-06-30 | AU$652.12 Million ≈ $461.41 Million |
-5.82% |
| 2018-06-30 | AU$692.44 Million ≈ $489.95 Million |
+5.61% |
| 2017-06-30 | AU$655.69 Million ≈ $463.94 Million |
-4.14% |
| 2016-06-30 | AU$684.02 Million ≈ $483.99 Million |
-32.80% |
| 2015-06-30 | AU$1.02 Billion ≈ $720.25 Million |
+13.19% |
| 2014-06-30 | AU$899.31 Million ≈ $636.32 Million |
+1.77% |
| 2013-06-30 | AU$883.71 Million ≈ $625.28 Million |
+22.66% |
| 2012-06-30 | AU$720.46 Million ≈ $509.77 Million |
-5.61% |
| 2011-06-30 | AU$763.25 Million ≈ $540.05 Million |
+1831.56% |
| 2010-06-30 | AU$39.51 Million ≈ $27.96 Million |
+46.49% |
| 2009-06-30 | AU$26.98 Million ≈ $19.09 Million |
-2.93% |
| 2008-06-30 | AU$27.79 Million ≈ $19.66 Million |
+30.84% |
| 2007-06-30 | AU$21.24 Million ≈ $15.03 Million |
+29.62% |
| 2006-06-30 | AU$16.38 Million ≈ $11.59 Million |
-23.67% |
| 2005-06-30 | AU$21.47 Million ≈ $15.19 Million |
-- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more